AAN 2023: Longer-term benefits seen with under-skin efgartigimod
Repeated treatment with under-the-skin efgartigimod had a consistent effect in easing symptoms of generalized myasthenia gravis (gMG), with no new safety issues identified. That’s according to interim data from the Phase 3 extension study ADAPT-SC+ (NCT04818671), which is…